Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

NCT01072695 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

HCV Infection

Interventions

DRUG: GS-9256
DRUG: GS-9190
DRUG: Ribavirin
DRUG: Peginterferon alfa-2a

Sponsor

Gilead Sciences